Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer
用户EO9nReo4Hj6s
19天前
36
10
已关闭
DOI: 10.1007/s40262-024-01451-7
文献链接: https://link.springer.com/10.1007/s40262-024-01451-7
其他信息:
出版社: Springer Science and Business Media LLC
作者: Mukul Minocha; Corbin G. Thompson; Alexis Murphy; Yanchen Zhou; Christian Brandl; Amanda Parkes; Xi Chen; Brian Yu; Pablo Martinez; Brett E. Houk
全文下载地址: https://link.springer.com/content/pdf/10.1007/s40262-024-01451-7.pdf
